Nervous Disorder TRIZ Cases

Framework-region amino acid substitutions raise TRBV9 antibody humanization while preserving affinity and solubility for pathogenic T-cell targeting.

Molecular sequence changes and PEG attachment extend calcitonin half-life, reducing injection frequency while maintaining therapeutic effect.

Polar lipid-rich Nannochloropsis oil boosts low-dose CBD bioavailability to improve sleep quality without the sedation seen with high-dose CBD.

Targeted Fc amino acid substitutions strengthen FcRn binding at pH 6.0 while preserving release at pH 7.4 to extend IgG serum half-life.

A PEG ester solubilizer and antioxidant keep capsaicin soluble and oxidation-resistant in aqueous injectable formulations during storage.

Guide RNA directs Cas9 to the SCN9A gene for precise, reproducible editing that reduces pain-related gene expression in one treatment.

Novel cereblon-binding small molecules improve substrate specificity and tumor cell death while reducing adverse effects of existing modulators.

Low-temperature trichome separation and staged alcohol extraction raise CBD while keeping THC below 0.5% for refractory epilepsy use.

An RE1-binding transcription factor vector enables glial-to-neuron conversion in vivo, overcoming poor efficacy of in vitro screened factors.

Selective compounds inhibit mTORC2 to reduce Aβ production, promote autophagy, and help prevent neuronal death in neurodegeneration.

Truncated calcitonin analogues with targeted amino acid changes improve neutral pH stability and extend half-life to reduce injection frequency.

Lowering brain oxygen through hemoglobin left-shifting or anemia helps counter mitochondrial dysfunction and improve neurological function.

Marker-based selection of Corin- and Lrtm1-positive progenitors improves survival, consistency, and cost in Parkinson's cell production.

Antibodies engineered to bind alpha-synuclein fibrils and monomers can block aggregation spread between neurons and reduce Lewy body pathology.

A tick-derived polypeptide reduces neuroinflammation and neuronal death after brain hemorrhage without increasing hemorrhage volume or edema.

Engineered anti-TREM2 antibodies promote extracellular-domain cleavage to consistently raise soluble TREM2 and enhance microglial phagocytosis.

VH4 antibodies with AGS mutations help target pathologic immune processes to reduce demyelination, inflammation, and axonal injury.

Combining adrenergic and RAAS-targeting agents helps treat multifactorial affective disorders by balancing cerebral blood flow and stress responses.

A buffered aqueous vigabatrin oral solution keeps pH at 5-8 to balance stability, solubility, taste, and patient compliance.

Codon-optimized PSEN1 delivered by AAV, exosomes, or lipid nanoparticles restores γ-secretase activity in Alzheimer's disease.

Low-dose intra-arterial ethyl alcohol opens the BBB uniformly for about 120 minutes, enabling targeted brain delivery with fewer adverse effects.

Targeting ApoE with therapeutic antibodies helps clear Aβ plaques, lowering plaque burden in Alzheimer's disease and cerebral amyloid angiopathy.

HSPC transplantation generates healthy microglia that reduce amyloid plaques and neuroinflammation while preserving memory in Alzheimer's models.

Genetic analysis identifies SIM2 variant carriers for targeted agonist therapy aimed at slowing or preventing Parkinson's disease progression.

Amphiphilic small molecules balance BBB permeability with selective Aβ oligomer binding to reduce neurotoxicity and support early AD imaging.

Gut microbiota restoration with antibiotics, bowel cleanse, and fecal transfer reduced core ASD severity and GI symptoms.

A rotational cam and spring-driven piston deliver precise transdermal bolus doses from a compact reservoir while reducing size, cost, and side effects.

A porous PLC wound film releases local analgesic for days, reducing painful dressing changes and limiting opioid use.

Combining marker-defined Schwann cell precursors or Schwann cells with NK cells improves neurotrophic secretion and nervous system regeneration.

Targeting TACE/ADAM17 with alpha1-antitrypsin helps reduce inflammation and oxidative stress while rescuing Schwann cells in CIDP.

Multi-stage extraction, winterization, and fractional distillation raise beta-caryophyllene yield from black pepper for terpene-rich nutraceutical extracts.

Nitric oxide-releasing MDA and MDMA prodrugs aim to improve depression and PTSD treatment by preserving therapeutic effects with better safety.

Specific fragrance compounds improve sleep duration, REM and deep sleep through olfactory pathways without invasive drug-based intervention.

An AAV vector delivers the ChAT gene to the CNS to restore cholinergic function and slow Alzheimer's progression beyond symptom relief.

Humanized anti-Tau antibodies improve brain delivery and Tau clearance while limiting edema and microhemorrhage at higher doses.

Glial-enriched progenitor cells are delivered near the infarct core to support myelin repair, cell integration, and recovery after white matter stroke.

Small molecules targeting the TLX ligand-binding domain tune coactivator binding and receptor stability to promote neurogenesis and treat cancer.

Short FPR-targeting peptide analogues extend in vivo half-life while modulating neutrophils and inflammatory cells to help control multiple sclerosis.

Anti-pro/latent myostatin antibodies address metabolic dysregulation while preserving lean muscle, reducing fat mass, and improving metabolic rate.

3-SPA blocks toxic Aβ42 oligomer formation while avoiding plaque-targeting antibody risks such as ARIA-E in Alzheimer's treatment.

Disrupting serine dehydratase raises serine while lowering deoxyceramide, offering a tissue-level alternative to restrictive dietary control.

Novel GPR17-modulating sulfonamides promote oligodendrocyte differentiation, enhance remyelination, and help protect axons.

Targeting Galectin-3 with antibodies reduces neuroinflammation and neural hyper-excitability in refractory epilepsy and related disorders.

A universal RNA-guided nuclease paired with modular guide RNA enables sequence-specific genome editing with lower design cost and complexity.

A cyclic peptide derivative uses tailored ring and substituent structure to selectively enhance astrocyte proliferation in nervous system cells.

Pridopidine targets ALS progression by restoring axonal transport, reducing mutant SOD1 aggregates, and helping preserve muscle and respiratory function.

Combining TLR4/MD2 pathway and EGFR inhibitors helps suppress tumor growth while delaying resistance in EGFR-resistant and wild-type cancers.

Formula (A) compounds use tailored aryl, alkynyl, and heteroaryl groups to selectively inhibit AKR1C3 with better pharmacokinetics and fewer side-effects.

Targeting the Sestrin-GATOR2 interface enables selective mTORC1 modulation for treating diseases linked to pathway dysregulation.

GLP-1 receptor agonists such as semaglutide are used to lower dementia risk and support cognitive function in patients with metabolic syndrome.